Economic and Social Impact of Drug Policies · 8.4 Burden on Health and Justice Systems

The criterion is partially established.

Mexico has national evidence on morbidity, mortality, disability, and the epidemiological burden associated with drug use disorders. Economic estimates for hepatitis C and a local cost-effectiveness study specifically focused on people who inject drugs in Tijuana are also available.

However, national hepatitis C costs are not disaggregated according to the fraction attributable to drug use, while the Tijuana evidence consists of local modeled scenarios. No national estimate integrates medical costs, disability, mortality, lost productivity, and out-of-pocket expenditure with controls for comorbidity and double counting.

The indicator therefore receives an orange classification. X is not activated because no international cooperation was identified that implemented a verifiable domestic system for measuring these attributable costs.